You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Portuguese genetic testing firm CGC Genetics recently launched a Diabetes/Obesity Mutation Panel that it claims can be used for preventive purposes.
CGC Genetics, a clinical genetics testing company, recently introduced a panel for skeletal dysplasias.
The assay runs on Illumina's digital microbead-based BeadXpress system, and bolsters the Porto, Portugal-based company's menu of Array CGC tests.
The Portugal-based testing company is one of a handful of firms to adopt the holographic microbead-based platform since the US Food and Drug Administration cleared the BeadXpress earlier this year.
Exiqon's Mircury LNA MicroRNA Arrays, CGC Genetics' Prenatal Diagnostic Test
CGC Genetics' Congenital Deafness Panel, EMD Millipore's CpGenome Turbo Kit
Oxford Gene Technology's CytoSure ISCA UPD 4 x 180K Array; CGC Genetics' Microarray Panels for the Diagnosis of Bardet-Biedl Syndrome, Thrombophilia, and Warfarin Pharmacogenetics
The Portuguese genetic testing company has located its US headquarters in Newark, NJ, and it has partnered with New Jersey Medical School's Institute of Genomic Medicine.
The Portuguese lab firm received its CLIA license less than a year after being among a handful of firms to receive a warning notice from California regulators.
NPR reports the US Food and Drug Administration has approved a treatment for a genetic disorder that causes rapid aging.
Late-stage testing indicates the AstraZeneca and Oxford University SARS-CoV-2 vaccine can have up to 90 percent efficacy, the Associated Press reports.
ScienceInsider reports Nature Communications is reviewing a paper on mentorship following social media criticism arguing it is sexist.
In PLOS this week: method to account for sequencing errors in phylogenies, study of influenza A in Switzerland, and more.